Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer - Fig 1

<p>The median progression free survival (A) and overall survival (B) in total patient population.</p

Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer - Fig 3

<p>Progression free survival according to prior numbers of systemic chemotherapy in total patient population (A) and in hormone receptor positive patients (B).</p

Previous studies of XP regimen in metastatic breast cancer patients previously treated with anthracycline and taxane.

<p>Previous studies of XP regimen in metastatic breast cancer patients previously treated with anthracycline and taxane.</p

Clinical outcomes.

<p>Clinical outcomes.</p

Characteristics of patient population.

<p>Characteristics of patient population.</p

Chemotherapy toxicities.

<p>Chemotherapy toxicities.</p

Univariate and multivariate analysis of progression free survival in HR positive patients.

<p>Univariate and multivariate analysis of progression free survival in HR positive patients.</p

Progression free survival according to hormone receptor status.

<p>Progression free survival according to hormone receptor status.</p